Vasculature News and Research

RSS

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Clinical Data, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pulmonary arterial hypertension (PAH) to PRX-8066, the Company's selective serotonin 2B (5-HT2B) receptor antagonist.

1 Nov 2010

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

Pathological protein deposits linked to Alzheimer's disease and cerebral amyloid angiopathy can be triggered not only by the administration of pathogenic misfolded protein fragments directly into the brain but also by peripheral administration outside the brain.

22 Oct 2010

Researchers identify common link among malignant tumor types in all grades of cancer

Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.

21 Oct 2010

Researchers develop new lab test for diagnosing preeclampsia

In as many as 8 percent of pregnancies worldwide, women who seem fine for months develop preeclampsia, a serious complication causing symptoms including high blood pressure, severe swelling, and problems with placental development. The untreatable and unpredictable condition, with no known cause, often requires premature delivery, and can sometimes kill the mother and the fetus.

15 Oct 2010

Lantheus announces Canadian launch of ABLAVAR injection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the Canadian launch of ABLAVAR (gadofosveset trisodium injection), a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent.

15 Oct 2010

Scientists discover 'switch' mechanism of lymphatic and blood vessel cells

Scientists at the University of East Anglia have made an important breakthrough in the way anti-cancer drugs are tested. A tumour cannot grow to a large size or spread until it has developed its own blood supply and leading research has looked for a way of halting capillary formation to stop tumours taking hold.But new findings published today in the Journal of Cell Science have shown that scientists testing such treatments may not have been studying exactly what they thought they were.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

Low-fat diet reduces risk of heart disease

Losing weight, especially among adults who are very heavy to obese, is a good way to prevent the onset of atherosclerosis, the artery-thickening condition that leads to potentially deadly heart disease. A diet that is low in either fats or carbohydrates can help reduce weight. But which one is the more heart-healthy?

8 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

FDA approves Medtronic's Integrity Coronary Stent System

Delivering another innovation for interventional cardiology, Medtronic, Inc.,announced today the U.S. Food and Drug Administration (FDA) approval of the Integrity Coronary Stent System. The new platform for Medtronic's coronary stents, including the Integrity bare-metal stent, is based on an advance in biomedical engineering called continuous sinusoid technology that enables the exploration of other breakthrough device concepts such as a polymer free drug filled stent.

21 Sep 2010

New imaging technique visualizes myocardial scar and heart's blood vessels simultaneously

Cardiologists and surgeons may soon have a new tool to improve outcomes for patients requiring pacemakers, bypass surgery or angioplasties. Research led by Dr. James White and his colleagues at The University of Western Ontario has led to a new imaging technique, which provides a single, 3D high-resolution image of the heart revealing both its vasculature and the presence of scar tissue within the muscle.

17 Sep 2010

Acceleron Pharma named as one of "Fierce 15" for 2010

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that it has been selected by the editors of FierceBiotech as one of the "Fierce 15" for 2010, an annual list of the top 15 most promising companies in the biotech industry.

15 Sep 2010

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.

14 Sep 2010

Avinger initiates enrollment in Wildcat Catheter trial for chronic total occlusions in femoropopliteal lesions

Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announces the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial. The CONNECT trial is a prospective, multi-center, non-randomized study intended to evaluate the Wildcat Catheter's ability to cross chronic total occlusions in femoropopliteal lesions.

10 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

Changes in Japan's MHLW reimbursement will drive chronic dialysis catheter market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, changes in Japan's Ministry of Health Labour and Welfare (MHLW) reimbursement, which encourage facilities to use higher-priced chronic dialysis catheters, will lead to double-digit growth in this segment over the next five years, and will support overall market revenues.

8 Sep 2010

Progerin may contribute to risk of atherosclerosis: Study

Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is a rare, fatal genetic disease characterized by an appearance of accelerated aging in children. All children with Progeria die of the same heart disease that affects millions of normal aging adults (atherosclerosis), but instead of occurring at 60 or 70 years of age, these children may suffer heart attacks and strokes even before age 10, and the average age of death is 13 years.